可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Givertz MM, Sawyer DB, Colicci WS, et al. A ntioxidants and myocardial contractility illuminating the“dark side ”of B-adrenergic receptor activation [J] . Circulation, 2001, 103(6):782-783.
[2] Sawyer DB, Colicci WS. Mitochondrial oxidative stress in heart failure: “oxygen wastage”revisited [J]. Circ R es, 2000, 86(2):119-120.
[3] Cesselli D, Jakoniuk I, Barlucchi L, et al. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy [J] . Circ Res, 2001, 89(3):198-200.
[4] Ma XL, Kumar S, Gao F, et al. Inhibition of p38 mitogen-activated protein kinase decrease cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion [J] . Circulation, 1999, 99(13):1685-1691.
[5] Eichhorn EJ, Bristow MR. The carvedilol prospective randomized cumulative survival(COPERNICUS) trial [J]. Curr Control T rials Cardiovasc Med, 2001, 2(1):20-23.
[6] Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial [J] . Lancet, 2001, 357(9266):1385- 1390.
[7] Abreu RM, Santos DJ, Moreno AJ, et al. Effects of Carvedilol and its analog BM 2910228 on mitochondrial function and oxidative stress [J]. J Pharmacol Exp Ther, 2000, 295(3):1022-1030.